Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma

<div>Immune checkpoints and the immunotherapeutic response indicator in different risk groups. (a) Expression of immune checkpoints among different risk groups. (b) IPS score between two groups. (c) The score of TIDE, MSI, MDSC, T-cell exclusion, and T-cell dysfunction between two groups.</div>

Genetics Research

fig5

Figure 5

Figure 5: Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma 

Figure 5 | Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma 